Strata Skin Sciences, Inc. (NASDAQ:SSKN) Short Interest Update

Strata Skin Sciences, Inc. (NASDAQ:SSKN) was the target of a significant increase in short interest in January. As of January 30th, there was short interest totaling 358,994 shares, an increase of 33.4% from the January 15th total of 269,078 shares. Approximately 10.3% of the company’s stock are short sold. Based on an average trading volume of 73,243 shares, the short-interest ratio is currently 4.9 days. Based on an average trading volume of 73,243 shares, the short-interest ratio is currently 4.9 days. Approximately 10.3% of the company’s stock are short sold.

Analysts Set New Price Targets

Several equities research analysts have recently commented on SSKN shares. Weiss Ratings restated a “sell (e+)” rating on shares of Strata Skin Sciences in a report on Thursday, January 22nd. Wall Street Zen raised shares of Strata Skin Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Strata Skin Sciences currently has a consensus rating of “Hold” and a consensus target price of $6.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Strata Skin Sciences stock. Azzad Asset Management Inc. ADV raised its holdings in Strata Skin Sciences, Inc. (NASDAQ:SSKN) by 81.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,800 shares of the medical device company’s stock after purchasing an additional 9,800 shares during the quarter. Azzad Asset Management Inc. ADV owned 0.41% of Strata Skin Sciences worth $45,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 32.43% of the company’s stock.

Strata Skin Sciences Stock Down 11.5%

Shares of SSKN traded down $0.05 during trading hours on Friday, reaching $0.35. 1,479,820 shares of the stock traded hands, compared to its average volume of 412,095. Strata Skin Sciences has a 52 week low of $0.28 and a 52 week high of $3.86. The company has a market cap of $2.03 million, a price-to-earnings ratio of -0.13 and a beta of 0.33. The stock has a fifty day simple moving average of $1.24 and a 200 day simple moving average of $1.58. The company has a current ratio of 0.95, a quick ratio of 0.75 and a debt-to-equity ratio of 10.22.

Strata Skin Sciences (NASDAQ:SSKN) last posted its quarterly earnings data on Thursday, November 13th. The medical device company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.12). Strata Skin Sciences had a negative net margin of 35.64% and a negative return on equity of 476.73%. The firm had revenue of $6.93 million during the quarter, compared to analysts’ expectations of $7.72 million. On average, equities analysts forecast that Strata Skin Sciences will post -1.05 EPS for the current year.

About Strata Skin Sciences

Strata Skin Sciences, Inc is a medical technology company headquartered in Edison, New Jersey, that specializes in developing and commercializing dermatological devices and therapies. The company’s flagship offering is the XTRAC® excimer laser system, an FDA‐cleared, 308-nanometer ultraviolet light device used to treat skin conditions such as vitiligo and psoriasis. Strata’s product suite also includes associated accessories and disposables, as well as clinical services and training programs designed to support dermatology practices and improve patient outcomes.

Strata Skin Sciences expanded its portfolio and market presence through the strategic acquisition of PhotoMedex in 2019, bringing together complementary phototherapy and energy-based technologies under one roof.